MBCL-31. TREATMENT RESULTS AMONG 106 PATIENTS WITH MEDULLOBLASTOMA OF MOLECULAR SUBGROUP 3
| Autor: | Olga Zheludkova, Svetlana Avanesyan, Svetlana Gorbatykh, Ivan Fisyun, L V Shishkina, Natalia Popova, Nadezhda Pishchaeva, Lyudmila Minkina, Alexander Matitsyn, Dmitriy Pogorelov, Yuri Kushel, Daniil Sakun, Marina Ryzhova, Andrey Golanov, Lyudmila Privalova, Vladislav Mitrofanov, Evgeny Matsekha, Artem Zaichikov, Ekaterina Grishina, L.V. Olkhova, Oleg Chulkov, V. E. Popov, Nikolay Vorobev, Olga Polushkina, Alexey Kislyakov, Sergey Kovalenko, Nadezhda Dunaeva, Andrey Korchunov, Irina Borodina, Alexander Shapochnik, Еugenia Inyushkina, Armen Melikyan, Marina Mushinskaya, Elena Slobina, Alexey Nechesnyuk, Natalia Yudina, Valentina Timofeeva, Evgeny Shultz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Neuro-Oncology |
| ISSN: | 1523-5866 1522-8517 |
| Popis: | OBJECTIVE To evaluate the treatment results among 106 patients of molecular subgroup 3 and to determine the factors affecting the prognosis. PATIENTS AND METHODS In all the patients, initial removal of the tumor was performed. All the patients got chemoradiotherapy according to the HIT protocol. There were 34girls and 72boys. Most patients were over 3 years:74 compared to 32 younger than 3. The majority of the patients had stage M+: 65; in 38 stage M0 was determined; in 3patients, stage was not specified, Mx.MYC amplification was found in 20 patients; MYCN amplification, in 4 patients. Classic medulloblastoma was predominant: 65, and 41 patients had anaplastic/large cell medulloblastoma. RESULTS The five-year progression-free survival was 0.51±0.05, the five-year overall survival was 0.52±0.04.The median survival was 82months,and the median progression-free survival was 37 months. There were no significant variations of PFS depending on the sex and age. The treatment results depended on the histological subtype: for classic medulloblastoma, the five-year PFS was 0.57; for the anaplastic/largecell,0.38(р = 0.02030). The presence of metastases significantly affected the survival: PFS for stage M0 was 0.77; for stage М+,0.35(р = 0.00062). Patients with MYC amplification had a significantly worse survival compared to MYCN patients and those without MYC amplification: 0.1, 0.75, and 0.58, respectively (р = 0.00002). Three patients with MYC amplification are alive: two patients had MGMT methylation detected. CONCLUSIONS The results of treatment among the patients with molecular subgroup 3 depended on the tumor subtype, presence of metastases, MYC amplification and MGMT methylation. In the absence of unfavorable factors, the survival was the same as in molecular subgroup 4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|